MUTANT MELANOMA
<em>NRAS</em>-mutant melanoma: current challenges and future prospect
... Abstract: Melanoma is one of the most common cutaneous cancers ...of melanoma is more aggressive and associated with poorer outcomes, compared to non-NRAS-mutant ...BRAF-mutant melanoma ...
7
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
... This analysis, representing the longest follow-up for any phase 3 trial evaluating BRAFi/MEKi combination therapy, demonstrated that long-term survival is achievable with D+T in a relevant proportion of patients with ...
26
MNK1/2 inhibition limits oncogenicity and metastasis of KIT mutant melanoma
... mucosal melanoma, in which KIT alterations are frequent, have been underwhelming, and only 20%–30% of acral and mucosal melanoma patients respond to anti–PD-1 immunotherapy (5, 24, 43, ...only ...
15
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
... -mutant melanoma brain ...attenuates melanoma cell growth in vitro and also inhibits brain metastasis formation in ...human melanoma brain metastases indicated a significant role of ...
19
MEK inhibitors for the treatment of NRAS mutant melanoma
... Abstract: Melanoma is increasing rapidly in incidence and prevalence, especially in younger females and older ...in melanoma, in particular the mitogen-activated protein kinase (MAPK) ...
13
The c-Jun/RHOB/AKT pathway confers resistance of BRAF -mutant melanoma cells to MAPK inhibitors
... BRAF-mutant melanoma patients to BRAF inhibitors is dramatically impaired by secondary resistances and rapid ...BRAF-mutant melanoma cells, inhibition of BRAF or its target MEK induces RHOB ...
15
Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/E BRAF mutant melanoma depends on JNK and TNF-α signaling
... malignant melanoma (MMM) is a highly aggressive tumor that is largely refractory to conventional anti-cancer chemotherapy ...BRAF mutant tumor cells ...BRAF mutant melanoma (28, ...
39
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
... metastatic melanoma patients who progress on treatment with BRAF inhibitor LGX818: resistant tumors will be biopsied and compared with a pretreatment biopsy to identify the mecha- nism of ...
12
Dabrafenib for treatment of<em> BRAF</em>-mutant melanoma
... 34. Hauschild A, Grob J, Dimidov LV, et al. An update on BREAK-3, a Phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). ...
9
Mitochondrial oxidative phosphorylation controls cancer cell’s life and death decisions upon exposure to MAPK inhibitors
... Although MAPK pathway inhibitors are becoming a promising anticancer strategy, they are insufficient to fully eliminate cancer cells and their long-term efficacy is strikingly limited in patients with BRAF-mutant ...
13
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
... mutated melanoma xenografts by up-regulation of VEGF-A and induction of angiogenesis ...NRAS mutant melanoma, neuroblastoma and lung cancer with GI50 values ranging between ...
10
Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
... three melanoma cell lines with BRAF ...BRAF mutant melanoma, which progressed after an initial response to ...that mutant NRAS leads to activation of MEK by signaling through RAF isoforms ...
11
Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.
... 5). Melanoma cells infected with rOka virus or the mutants rOka D gI, rOka D gI-N, rOka D gI-C, rOka- gI@Avr#9, and rOka-gI@Avr#14 were stained with the an- ti-gE monoclonal 3G8 and TR ceramide 32 h after ...
10
Variation of mutant allele frequency in NRAS Q61 mutated melanomas
... NRAS mutant allele increase in the proportion of NRAS mutated melanoma, we firstly performed FISH analyses with 2 BAC probes covering NRAS region and another region of chromo- some 1, telomeric to this ...
10
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
... It has recently been shown that tumor cell metabolism can be exploited to treat cancer [15]. In the 1920s, Otto Warburg found that cancer cells consume very high rates of glucose and secrete large amounts of lactate in ...
11
Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H
... a mutant p53 R175H [29, 41]. Cytofluorometric live- dead analysis indicated a majority of live cells in control cultures or in those singly treated with DSF or SOD. However, SOD cooperated with DSF to increase the ...
11
<p>Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey</p>
... Table 2 shows the fi rst-line systemic treatments used in WE and the USA, strati fi ed by BRAF mutation status. IO drugs were by far the preferred treatment for the metastatic melanoma patient with wild-type BRAF. ...
7
Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
... of melanoma have led to a new era of melanoma treatment with targeted therapy and ...allow melanoma to be treated at many different stages in its ...of melanoma up to the latest agents ...
9
PIM kinases as therapeutic targets against advanced melanoma
... 3D melanoma models. (A) Melanoma cells were treated with increasing doses of SGI-1776 or AZD6482 for 72 h and were assessed using the alamarBlue ...embedded melanoma spheroids were treated for 72 h ...
16
Differentiation of Varicella-Zoster Virus ORF47 Protein Kinase and IE62 Protein Binding Domains and Their Contributions to Replication in Human Skin Xenografts in the SCID-hu Mouse
... To investigate the role of the ORF47 protein kinase of varicella-zoster virus (VZV), we constructed VZV recombinants with targeted mutations in conserved motifs of ORF47 and a truncated ORF47 and character- ized these ...
11